| Jul 23 |
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
|
| Jul 23 |
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
|
| Jul 22 |
3 Gene Editing Stocks Shaping the Future of Medicine
|
| Jul 20 |
3 Monster Stocks in the Making to Buy Right Now
|
| Jul 18 |
Institutional investors must be pleased after a 8.9% gain last week that adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) one-year returns
|
| Jul 17 |
3 Gene Editing Stocks That Could Grow Your Wealth
|
| Jul 17 |
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
|
| Jul 17 |
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
|
| Jul 16 |
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
|
| Jul 13 |
Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
|
